Filing Flows › Ensysce Biosciences (ENSC) › R&D spending
Ensysce Biosciences (ENSC) R&D spending by quarter
Ensysce Biosciences' R&D spending was $2.5M in Q2 2026 (second quarter 2026), -26% from Q1 2026. Over the last 7 quarters it ranged from $1.9M (Q1 2025) to $3.8M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.5M | -26% | +29% |
| Q1 2026 | $3.3M | -7% | +78% |
| Q4 2025 | $3.6M | +22% | -5% |
| Q3 2025 | $3.0M | +54% | — |
| Q2 2025 | $1.9M | +2% | — |
| Q1 2025 | $1.9M | -50% | — |
| Q4 2024 | $3.8M | — | — |
Q2 2026 at a glance
Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%, net loss $2.6M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ensysce Biosciences' R&D spending?
Ensysce Biosciences' R&D spending was $2.5M in Q2 2026 (second quarter 2026), -26% from Q1 2026.
How has Ensysce Biosciences' R&D spending changed?
Over the last 7 quarters it ranged from $1.9M (Q1 2025) to $3.8M (Q4 2024).